Dr. Reddy’s Laboratories Launches Aspirin and Extended-Release Dipyridamole Capsules in the U.S. Market

- December 24th, 2018

Dr. Reddy’s Laboratories (BSE:500124,NSE:DRREDDY,NYSE:RDY), along with its subsidiaries together referred to as “Dr. Reddy’s”, today announced the launch of Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) Capsules in the United States market from the U.S. Food and Drug Administration (USFDA). As quoted in the press release: … Continued

Dr. Reddy’s Laboratories (BSE:500124,NSE:DRREDDY,NYSE:RDY), along with its subsidiaries together referred to as “Dr. Reddy’s”, today announced the launch of Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) Capsules in the United States market from the U.S. Food and Drug Administration (USFDA).

As quoted in the press release:

The Aggrenox brand and generic had U.S. sales of approximately $182 million MAT for the most recent twelve months ending in October 2018 according to IMS Health*.

Dr. Reddy’s Aspirin and Extended-Release Dipyridamole Capsules are available in 25 mg/200 mg strength with 60 count bottle size. Aggrenox is a trademark of Boehringer Ingelheim. *IMS National Sales Perspective: Retail and Non-Retail MAT October 2018
RDY-1218-230

Click here to read the full press release.

Find out what experts are saying about the future of cannabis

 
Read our 2019 conference report today
 

Leave a Reply